Cellectar Biosciences, Inc.
CLRB
$4.77
$0.06831.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 22.66% | -54.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.68% | -49.78% | |||
| Operating Income | 5.68% | 49.78% | |||
| Income Before Tax | 17.51% | -188.46% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 17.51% | -180.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.51% | -180.38% | |||
| EBIT | 5.68% | 49.78% | |||
| EBITDA | 5.72% | 49.95% | |||
| EPS Basic | 21.24% | -155.18% | |||
| Normalized Basic EPS | 21.24% | -162.55% | |||
| EPS Diluted | 21.15% | -155.18% | |||
| Normalized Diluted EPS | 21.24% | -162.55% | |||
| Average Basic Shares Outstanding | 4.74% | 9.87% | |||
| Average Diluted Shares Outstanding | 4.74% | 9.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||